NEW YORK (GenomeWeb News) – Oxford Gene Technology has acquired protein array firm Sense Proteomic for an undisclosed sum.

UK-based Sense Proteomic has identified biomarker panels for a variety of diseases including prostate cancer and lupus. According to OGT, Sense Proteomic's technology can identify a stage of disease by monitoring changes in autoantibody production during disease progression and also can be used to monitor response to therapeutic interventions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.